WO2008035131A1 - An improved process for the preparation of bisphosphonic acid - Google Patents
An improved process for the preparation of bisphosphonic acid Download PDFInfo
- Publication number
- WO2008035131A1 WO2008035131A1 PCT/IB2006/002588 IB2006002588W WO2008035131A1 WO 2008035131 A1 WO2008035131 A1 WO 2008035131A1 IB 2006002588 W IB2006002588 W IB 2006002588W WO 2008035131 A1 WO2008035131 A1 WO 2008035131A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- preparation
- formula
- phosphorous
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Definitions
- the present invention relates to an improved process for the preparation of bisphosphonic acid of formula (I) and its pharmaceutically acceptable salts thereof,
- R represents-NRiR. 2
- n 1,2,3,4 and 5, where Ri and R 2 independently represents hydrogen,C I-6 alkyl.
- the bisphosponates which are salts of bisphosphonic acids, are an important class of medicaments useful in the treatment of bone disorders such as Paget's disease and osteoporosis.
- the sodium salt of risedronic acid, sodium salt of pamidronic acid, sodium salt of alendronic acid are the examples of pharmaceutically useful bisphosphonates.
- the bisphosphonates are derived from the corresponding bisphosphonic acids.
- Several methods have been reported for preparing 1 -hydroxy- 1,1 -bisphosphonic acids. The syntheses are based on reacting a carboxylic acid with a mixture of phosphorous acid and one of the following phosphorous halides: phosphorous trichloride (PCl 3 ), phosphorous oxychloride (POCl 3 ), phosphorous pentachloride (PCl 5 ), phosphorous tribromide (PBr 3 ), phosphorous oxybromide (POBr 3 ) or phosphorous pentabromide (PBr 5 ), then quenching the reaction mixture with water or a nonoxidizing aqueous acid, followed by heating to hydrolyze the phosphorous intermediates to the final product.
- PCl 3 phosphorous trichloride
- POCl 3 phosphorous oxychloride
- PCl 5 phosphorous pentachloride
- PBr 3 phosphorous tribro
- U.S. Patent 5,908,959 also describes the preparation of 4-amino-l- hydroxybutylidene-l,l-biphosphonic acid or salts.- thereof.
- the reaction is carried out in poly (alkylene glycol) as a diluent, which solubilizes the reaction components, however still when the reaction mixture is decomposed with water, an agitation problem occurs.
- the viscous reaction mixture must be transferred into the water.
- viscosity problem is solved by the addition of toluene. When using toluene, a safety problem arises and also an additional separation step is needed.
- the present invention solves the problems by allowing the reaction to remain stirrable using anisole as solvent, and making commerical manufacturing possible thus allowing complete conversion of the carboxylic acid providing excellent yields and purity of the formula (I).
- the main objective of the present invention is to provide an improved process using anisole as solvent for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof.
- Another objective of the present invention is to provide a process for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof, which would be easy to implement on commercial scale, which can avoid the use of hazardous chemicals like methane sulfonic acid, chloro benzene and toluene.
- Still another objective of the present invention is to provide a process for the preparation of compound of formula (I) and its pharmaceutically acceptable salts in good yield and high purity.
- the present invention provides an improved process for the preparation of bisphosphonic acid of formula (I) and its pharmaceutically acceptable salts thereof,
- the method of making a bisphosphonic acid comprising the steps of: i) reacting carboxylic acid of formula (II) with a mixture of phosphorous acid and PCl 3 in the presence of solvent anisole at a temperature of about 100 -115 0 C , ii) Combining the reaction mixture with water, whereby an aqueous and a non - aqueous phase are formed , iii) separating the aqueous layer and neutralize with sodium hydroxide solution, iv) combining the aqueous phase with methanol whereby a suspension comprising bisphosphonic acid is formed , and v) isolating the compound of formula (I) or salts thereof .
- the carboxylic acid of formula (II) is selected from 4-aminobutanoic acid, (3-pyridyl) ethanoic acid, (1-imidazoyl) ethanoic acid, N-(n-pentyl)-N-methyl-3-aminopropanoic acid, 2(imidazo[l,2-a]pyridin-3- yl)ethanoic acid,3-aminopropanoic acid and 6-aminohexanoic acid, and the hydrochlorides thereof.
- the phosphonating reagent selected from a mixture of phosphorous acid and a halophosporous compound selected from phosphorous trichloride (PCl 3 ), phosphorous pentachloride (PCI 5 ), phosphorous tribromide (PBr 3 ), phosphorous pentabromide (PBrs ) , Phosphorous oxybromide
- the bisphosphonation reaction generally takes place at a temperature of from 45 0 C to 125 0 C, preferably in the range of 100-115 0 C.
- the quenching temperature is in the range of 50 0 C to reflux and preferably at the reflux temperature of about 105- 115 0 C.
- compound of formula (I) is further converted to pharmaceutically acceptable salts such as potassium, sodium, calcium or magnesium and the like by conventional methods.
- the solvent is separated and water (400 ml) is added slowly under stirring. Heating and stirring started again and refluxed the mass for 5-6 hrs at 110- 115 0 C. It is then cooled to 28-30°C.The trapped solvent and aqueous phases are separated. The aqueous phase is cooled to 20-25 0 C and pH of the solution is adjusted to 1.8 by using caustic lye solution. To this solution, methanol is added slowly to precipitate of the crude alendronic acid and filtered (230-250 gm).
- the crude alendronic acid obtained above is taken in a 1-lt flask equipped with mechanical stirrer, a reflux condenser and deminaralized water (500 ml) is charged in to it, heated the mixture to 70 0 C under stirring and then the pH of the suspension is adjusted to 1.8 using cone, hydrochloric acid.
- the suspension is heated to 80-85 0 C under stirring and stirred for 3-4 hrs and then cooled gradually to 28-30 0 C in 2 hrs.
- the pH of the suspension is 1.7-2.0 and aged for lhr at 28-30 0 C.
- the product is collected by filtration.
- the yield of alendronic acid after drying at 60-65 0 C under vacuum until constant weight is 166.9 gm ( ⁇ 90%).
- the product crystallized is filtered, washed with 50 ml cold deminaralized water and then dried to yield 105.3 gm of alendronate sodium trihydrate.
- the yield of the product on the basis of 4-amino butyric acid is 1.76w/w.
Abstract
The present invention is to relate an improved process using anisole as solvent for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof. wherein R represents-NR1R2, or formula (II), a group n = 1,2,3,4 and 5, where R1 and R2 may be same or different and independently represents hydrogen, or C1-6 alkyl;
Description
AN IMPROVED PROCESS FOR THE PREPARATION OF BISPHOSPHONIC ACH)
Field of the invention: The present invention relates to an improved process for the preparation of bisphosphonic acid of formula (I) and its pharmaceutically acceptable salts thereof,
Wherein R represents-NRiR.2,
n = 1,2,3,4 and 5, where Ri and R2 independently represents hydrogen,C I-6 alkyl.
Background of the invention:
The bisphosponates, which are salts of bisphosphonic acids, are an important class of medicaments useful in the treatment of bone disorders such as Paget's disease and osteoporosis. The sodium salt of risedronic acid, sodium salt of pamidronic acid, sodium salt of alendronic acid are the examples of pharmaceutically useful bisphosphonates.
The bisphosphonates are derived from the corresponding bisphosphonic acids. Several methods have been reported for preparing 1 -hydroxy- 1,1 -bisphosphonic acids. The syntheses are based on reacting a carboxylic acid with a mixture of phosphorous acid and one of the following phosphorous halides: phosphorous trichloride (PCl3), phosphorous oxychloride (POCl3), phosphorous pentachloride (PCl5), phosphorous tribromide (PBr3), phosphorous oxybromide (POBr3) or phosphorous pentabromide
(PBr5), then quenching the reaction mixture with water or a nonoxidizing aqueous acid, followed by heating to hydrolyze the phosphorous intermediates to the final product.
The preparation of 3-amino-l-hydroxypropane-l,l-diphosphonic acid by reaction of beta.-alanine with a mixture of phosphorous trichloride and phosphorous acid in the presence or absence of an organic diluent is known from the German Patent
Specification No. 21 30 794. However, yellow-red by-products in the form of amorphous phosphorus-oxygen compounds of unknown structure are formed in this reaction and their separation, particularly in the presence of chlorobenzene, is very costly. Another factor to be considered in the large scale preparations is the dangerously high flammability of these phosphorus compounds
In U.S. Patent 4,407,761 the preparation of 4-amino-l-hydroxybutylidene-l,l- biphosphonic acid besides other bisphosphonic acids are described. When using this procedure, a semisolid sticky non-stirrable mass develops which prevents smooth heat transfer. The described process might be suitable for-laboratory preparations, however for industrial production it is not acceptable.
In U.S. Patent 4,705,651 a similar procedure is followed with different molar ratios and although some improvements were achieved, it is still unsuitable for industrial scale up.
U.S. Patents 4,922,007, 5,019,651 and J. Org. Chem. 1995, 60, 8310-8312 reported that the solidification problem has been solved by using methanesulfonic acid to solubilize the reaction components and keep them fluid throughout, by the use of methanesulfonic acid the fluidity problems were solved however another serious safety problem surfaced. A reaction between methanesulfonic acid and phosphorus trichloride is exothermic and at certain point becomes uncontrollable,
U.S. Patent 5,908,959 also describes the preparation of 4-amino-l- hydroxybutylidene-l,l-biphosphonic acid or salts.- thereof. The reaction is carried out in poly (alkylene glycol) as a diluent, which solubilizes the reaction components, however still when the reaction mixture is decomposed with water, an agitation problem occurs. The viscous reaction mixture must be transferred into the water. To
facilitate this, viscosity problem is solved by the addition of toluene. When using toluene, a safety problem arises and also an additional separation step is needed.
The present invention solves the problems by allowing the reaction to remain stirrable using anisole as solvent, and making commerical manufacturing possible thus allowing complete conversion of the carboxylic acid providing excellent yields and purity of the formula (I).
Objectives of the invention: The main objective of the present invention is to provide an improved process using anisole as solvent for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof.
Another objective of the present invention is to provide a process for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof, which would be easy to implement on commercial scale, which can avoid the use of hazardous chemicals like methane sulfonic acid, chloro benzene and toluene.
Still another objective of the present invention is to provide a process for the preparation of compound of formula (I) and its pharmaceutically acceptable salts in good yield and high purity.
Summary of the invention:
Accordingly, the present invention provides an improved process for the preparation of bisphosphonic acid of formula (I) and its pharmaceutically acceptable salts thereof,
The process is shown in the scheme given below
R-(C
Detailed description of the invention:
In an embodiment of the .present invention the carboxylic acid of formula (II) is selected from 4-aminobutanoic acid, (3-pyridyl) ethanoic acid, (1-imidazoyl) ethanoic acid, N-(n-pentyl)-N-methyl-3-aminopropanoic acid, 2(imidazo[l,2-a]pyridin-3- yl)ethanoic acid,3-aminopropanoic acid and 6-aminohexanoic acid, and the hydrochlorides thereof.
In another embodiment of the present invention the phosphonating reagent selected from a mixture of phosphorous acid and a halophosporous compound selected from phosphorous trichloride (PCl3), phosphorous pentachloride (PCI5), phosphorous tribromide (PBr3), phosphorous pentabromide (PBrs), Phosphorous oxybromide
(POBr3), phosphorous oxychloride (POCl3 ) and the like or mixtures thereof.
In yet another embodiment of the present invention the bisphosphonation reaction generally takes place at a temperature of from 45 0C to 125 0C, preferably in the range of 100-115 0C.
In yet another embodiment of the present invention the quenching temperature is in the range of 50 0C to reflux and preferably at the reflux temperature of about 105- 115 0C.
In another embodiment compound of formula (I) is further converted to pharmaceutically acceptable salts such as potassium, sodium, calcium or magnesium and the like by conventional methods.
The present invention is exemplified by the following example, which is provided for illustration only and should not be construed to limit the scope of the invention.
Example 1
Preparation of 4-atnino-l-hydroxybutylidene-l, 1-biphosphonic acid mono sodium salt trihydrate.
Step- (I)-Preparation of Alendronic acid
100 gm (0.97 mol) of 4-Aminobutyric acid (GABA), 1 19.3 gm (1.45 mol) of phosphorous acid and 600 ml of anisole are charged in a dry and nitrogen flushed 21t flask fitted a mechanical stirrer, a thermometer pocket, an addition funnel and a reflux condenser that circulated with chilled water. The mixture is heated upto 60-700C and then charged slowly phosphorous trichloride 333.0 gm (2.42 mol) under vigorous stirring in 40-45 minutes at 60-700C. The reaction mixture is heated to 100-1050C and stirred for 5 hrs until the HCl gas evaluation is completely stopped and then the mass is allowed to cool. The solvent is separated and water (400 ml) is added slowly under stirring. Heating and stirring started again and refluxed the mass for 5-6 hrs at 110- 1150C. It is then cooled to 28-30°C.The trapped solvent and aqueous phases are separated. The aqueous phase is cooled to 20-250C and pH of the solution is adjusted to 1.8 by using caustic lye solution. To this solution, methanol is added slowly to precipitate of the crude alendronic acid and filtered (230-250 gm).
The crude alendronic acid obtained above is taken in a 1-lt flask equipped with mechanical stirrer, a reflux condenser and deminaralized water (500 ml) is charged in to it, heated the mixture to 700C under stirring and then the pH of the suspension is adjusted to 1.8 using cone, hydrochloric acid. The suspension is heated to 80-850C under stirring and stirred for 3-4 hrs and then cooled gradually to 28-300C in 2 hrs. The pH of the suspension is 1.7-2.0 and aged for lhr at 28-300C. The product is collected by filtration. The yield of alendronic acid after drying at 60-650C under vacuum until constant weight is 166.9 gm (~ 90%).
StepdD -Preparation of sodium salt as trihydrate:
100 gm of 4-amino-l-hydroxybutylidene-l, 1-biphosphonic acid is suspended in 500 ml of deinoised water with vigorous stirring at 30 to 70°C.The pH of the suspension is adjusted to 4.4-4.6 by using 30 %w/w aqueous solution of sodium hydroxide to form a clear solution. The clear solution is filtered through a filter medium to remove fine foreign particles if any and the filtered solution is aged overnight at 2- 4°C.
The product crystallized is filtered, washed with 50 ml cold deminaralized water and then dried to yield 105.3 gm of alendronate sodium trihydrate. The yield of the product on the basis of 4-amino butyric acid is 1.76w/w.
Claims
1. A process for the preparation of bisphosphonic acid of the formula (I) or its pharmaceutically acceptable salts thereof
(i) reacting the carboxylic acid of formula (II)
R-(CH2 )n-COOH
(II) wherein R is defined above; with phosphorous acid and a halophosporous compound in the presence of anisole at 45 -120 0C, and (ii) isolating the compound of formula (I).
2. A process according to claim 1, wherein the halophosporous compound is selected from PCl3, PC15, PBr3, PBr5, POBr3, or POCl3.
3. A process according to claim 1, wherein said reaction is conducted at a temperature in the range of 100-1150C.
4. A process according to claim 1, wherein the pharmaceutically acceptable salt is selected from sodium, potassium, calcium or magnesium.
5. A process according to claim I5 wherein the pharmaceutically acceptable salt is sodium.
6. The process as claimed in claim 1 is the preparation of alendronic acid, pamidronic acid, risedronic acid, zoledronic acid, ibandronic acid, minodronic acid and neridronic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/002588 WO2008035131A1 (en) | 2006-09-19 | 2006-09-19 | An improved process for the preparation of bisphosphonic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/002588 WO2008035131A1 (en) | 2006-09-19 | 2006-09-19 | An improved process for the preparation of bisphosphonic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008035131A1 true WO2008035131A1 (en) | 2008-03-27 |
Family
ID=39200220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2006/002588 WO2008035131A1 (en) | 2006-09-19 | 2006-09-19 | An improved process for the preparation of bisphosphonic acid |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008035131A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102020676A (en) * | 2010-12-03 | 2011-04-20 | 南京华威医药科技开发有限公司 | Method for preparing minodronate |
| US8524912B2 (en) | 2008-10-31 | 2013-09-03 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of [1-hydroxy-2-(1H-imidazol-1-yl)- ethylidene]bisphosphonic acid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2082585A (en) * | 1980-08-27 | 1982-03-10 | Vysoka Skola Chem Tech | 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts. |
-
2006
- 2006-09-19 WO PCT/IB2006/002588 patent/WO2008035131A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2082585A (en) * | 1980-08-27 | 1982-03-10 | Vysoka Skola Chem Tech | 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts. |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8524912B2 (en) | 2008-10-31 | 2013-09-03 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of [1-hydroxy-2-(1H-imidazol-1-yl)- ethylidene]bisphosphonic acid |
| CN102020676A (en) * | 2010-12-03 | 2011-04-20 | 南京华威医药科技开发有限公司 | Method for preparing minodronate |
| CN102020676B (en) * | 2010-12-03 | 2013-01-09 | 南京华威医药科技开发有限公司 | Method for preparing minodronate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1891081B1 (en) | Process for producing bisphosphonic acids and forms thereof | |
| US7361761B2 (en) | Process for the preparation of bisphosphonic acid | |
| JP4642762B2 (en) | Method for producing bisphosphonic acid compound | |
| US7439385B2 (en) | Process for the preparation of biphosphonic derivatives | |
| US7528280B2 (en) | Process for the preparation of biphosphonic acids | |
| EP1504012B9 (en) | Preparation of biphosphonic acids and salts thereof | |
| US20080194525A1 (en) | Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof | |
| US8450488B2 (en) | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof | |
| US8779135B2 (en) | Method for the manufacture of aminohydroxy diphosphonic acids | |
| EP1390373B9 (en) | Process for the preparation of 4-amino-1-hydroxybutylidene-1, 1-biphosphonic acid | |
| WO2014091386A2 (en) | An improved process for preparation of minodronic acid | |
| WO2008035131A1 (en) | An improved process for the preparation of bisphosphonic acid | |
| JP2010508376A (en) | Method for producing biphosphonic acid and salt thereof | |
| SK11862001A3 (en) | Novel process for preparing alendronic acid | |
| PL213599B1 (en) | Method of obtaining of [1-hydroxy-2-(1H-imidazole-1-yl)-ethylidene] bisphosphonic acid | |
| US20100317859A1 (en) | Process for the Preparation of Risedronate Sodium | |
| WO2007010556A1 (en) | Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof | |
| KR100877667B1 (en) | Method of Preparing a Risedronate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06808857 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06808857 Country of ref document: EP Kind code of ref document: A1 |